<DOC>
	<DOCNO>NCT01414816</DOCNO>
	<brief_summary>To identify problems/questions follow item clinical practice use Betaferon 1 . Unknown adverse event ( especially serious adverse event ) 2 . Identification adverse event occur real practice 3 . Factors may affect safety drug 4 . Factors may affect effectiveness drug</brief_summary>
	<brief_title>BetaferonÂ® Regulatory Post-Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients diagnosis MS CIS decision take physician prescribe Betaferon Patients participate Betaferon regulatory Post Marketing Surveillance . Exclusion criterion must read conjunction local product information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Clinical Isolated Syndrome ( CIS )</keyword>
</DOC>